Phase 1 Study of Nivolumab in Combination with Tocilizumab for Treatment of Patients with Relapsed Hematological Malignancy Post-Allogeneic Transplant

Protocol No
IIT-SHAH-TOCI4-NIVOLUMAB
Principal Investigator
Nirav Shah
Phase
I
Summary
Evaluate the safety of the combination of Nivolumab and Tocilizumab and to determine the best dose for treating adults with relapsed disease after an allogeneic transplant.
Description
Nivolumab in Combination with Tocilizumab for Patients with Relapsed Hematological Malignancy post Bone Marrow Transplant
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: